Weight gain is associated with improved glycaemic control but with adverse changes in plasma lipids and blood pressure isn Type 1 diabetes.

Hdl Handle:
http://hdl.handle.net/10147/208848
Title:
Weight gain is associated with improved glycaemic control but with adverse changes in plasma lipids and blood pressure isn Type 1 diabetes.
Authors:
Ferriss, J B; Webb, D; Chaturvedi, N; Fuller, J H; Idzior-Walus, B
Affiliation:
Department of Medicine, Cork University Hospital, Wilton, Cork, Ireland., b.ferriss@ucc.ie
Citation:
Diabet Med. 2006 May;23(5):557-64.
Journal:
Diabetic medicine : a journal of the British Diabetic Association
Issue Date:
3-Feb-2012
URI:
http://hdl.handle.net/10147/208848
DOI:
10.1111/j.1464-5491.2006.01847.x
PubMed ID:
16681565
Abstract:
AIMS: To assess the effects of weight gain on metabolic control, plasma lipids and blood pressure in patients with Type 1 diabetes. METHODS: Patients in the EURODIAB Prospective Complications Study (n = 3250) were examined at baseline and 1800 (55%) were re-examined a mean of 7.3 years later. Patients had Type 1 diabetes, defined as a diagnosis made before age 36 years and with a need for continuous insulin therapy within a year of diagnosis. Patients were aged 15-60 years at baseline and were stratified for age, sex and duration of diabetes. RESULTS: The change in HbA(1c) from baseline to follow-up examination was significantly more favourable in those who gained 5 kg or more during follow-up ('marked weight gain') than in patients who gained less or no weight or lost weight ('less or no weight gain'). In those with marked weight gain, there was a significantly greater rise in plasma triglycerides and total cholesterol and significantly less favourable changes in low-density lipoprotein and high-density lipoprotein cholesterol compared with those with less or no weight gain, with or without adjustment for HbA(1c). Systolic and diastolic blood pressure also rose significantly more in the group with marked weight gain. CONCLUSION: Weight gain in patients with Type 1 diabetes has adverse effects on plasma lipids and blood pressure, despite a small improvement in glycaemic control.
Language:
eng
MeSH:
Adolescent; Adult; Blood Glucose/*analysis; Blood Pressure/physiology; Cholesterol/blood; Diabetes Mellitus, Type 1/metabolism/*physiopathology; Drug Administration Schedule; Female; Hemoglobin A, Glycosylated/analysis; Humans; Hypoglycemic Agents/administration & dosage; Injections; Insulin/administration & dosage; Lipids/*blood; Lipoproteins/blood; Male; Middle Aged; Prospective Studies; Triglycerides/blood; Waist-Hip Ratio; Weight Gain/*physiology
ISSN:
0742-3071 (Print); 0742-3071 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorFerriss, J Ben_GB
dc.contributor.authorWebb, Den_GB
dc.contributor.authorChaturvedi, Nen_GB
dc.contributor.authorFuller, J Hen_GB
dc.contributor.authorIdzior-Walus, Ben_GB
dc.date.accessioned2012-02-03T15:05:20Z-
dc.date.available2012-02-03T15:05:20Z-
dc.date.issued2012-02-03T15:05:20Z-
dc.identifier.citationDiabet Med. 2006 May;23(5):557-64.en_GB
dc.identifier.issn0742-3071 (Print)en_GB
dc.identifier.issn0742-3071 (Linking)en_GB
dc.identifier.pmid16681565en_GB
dc.identifier.doi10.1111/j.1464-5491.2006.01847.xen_GB
dc.identifier.urihttp://hdl.handle.net/10147/208848-
dc.description.abstractAIMS: To assess the effects of weight gain on metabolic control, plasma lipids and blood pressure in patients with Type 1 diabetes. METHODS: Patients in the EURODIAB Prospective Complications Study (n = 3250) were examined at baseline and 1800 (55%) were re-examined a mean of 7.3 years later. Patients had Type 1 diabetes, defined as a diagnosis made before age 36 years and with a need for continuous insulin therapy within a year of diagnosis. Patients were aged 15-60 years at baseline and were stratified for age, sex and duration of diabetes. RESULTS: The change in HbA(1c) from baseline to follow-up examination was significantly more favourable in those who gained 5 kg or more during follow-up ('marked weight gain') than in patients who gained less or no weight or lost weight ('less or no weight gain'). In those with marked weight gain, there was a significantly greater rise in plasma triglycerides and total cholesterol and significantly less favourable changes in low-density lipoprotein and high-density lipoprotein cholesterol compared with those with less or no weight gain, with or without adjustment for HbA(1c). Systolic and diastolic blood pressure also rose significantly more in the group with marked weight gain. CONCLUSION: Weight gain in patients with Type 1 diabetes has adverse effects on plasma lipids and blood pressure, despite a small improvement in glycaemic control.en_GB
dc.language.isoengen_GB
dc.subject.meshAdolescenten_GB
dc.subject.meshAdulten_GB
dc.subject.meshBlood Glucose/*analysisen_GB
dc.subject.meshBlood Pressure/physiologyen_GB
dc.subject.meshCholesterol/blooden_GB
dc.subject.meshDiabetes Mellitus, Type 1/metabolism/*physiopathologyen_GB
dc.subject.meshDrug Administration Scheduleen_GB
dc.subject.meshFemaleen_GB
dc.subject.meshHemoglobin A, Glycosylated/analysisen_GB
dc.subject.meshHumansen_GB
dc.subject.meshHypoglycemic Agents/administration & dosageen_GB
dc.subject.meshInjectionsen_GB
dc.subject.meshInsulin/administration & dosageen_GB
dc.subject.meshLipids/*blooden_GB
dc.subject.meshLipoproteins/blooden_GB
dc.subject.meshMaleen_GB
dc.subject.meshMiddle Ageden_GB
dc.subject.meshProspective Studiesen_GB
dc.subject.meshTriglycerides/blooden_GB
dc.subject.meshWaist-Hip Ratioen_GB
dc.subject.meshWeight Gain/*physiologyen_GB
dc.titleWeight gain is associated with improved glycaemic control but with adverse changes in plasma lipids and blood pressure isn Type 1 diabetes.en_GB
dc.contributor.departmentDepartment of Medicine, Cork University Hospital, Wilton, Cork, Ireland., b.ferriss@ucc.ieen_GB
dc.identifier.journalDiabetic medicine : a journal of the British Diabetic Associationen_GB
dc.description.provinceMunster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.